Fas-mediated induction of hepatocyte apoptosis in a neuroblastoma and hepatocyte coculture model

Journal of Surgical Research

Volumn 84, Issue 1, 1999, Pages 82-87

  Chen, Mike K ^a   Strande, Louise F ^a   Beierle, Elizabeth A ^a   Kain, Michael S ^a   Geldziler, Brian D ^a   Doolin, Edward J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Fas; Fas ligand; Hepatocytes; Neuroblastoma; Tumor necrosis factor

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL CONTACT; CELL LEVEL; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INDUCTION; REGULATORY MECHANISM;

EID: 0033150171     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5614     Document Type: Article

References (46)

1. von Reyher U., Strater J., Kittstein W., Gschwendt M., Krammer P. H., Moller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 58:1998;526.
2. Strand S., Hofmann W. J., Hug H., Muller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion. Nat. Med. 2:1996;1361.
3. Hedlund T. E., Duke R. C., Schleicher M. S., Miller G. J. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage. Prostate. 36:1998;92.
4. Nunez G., Seto M., Seremetis S., Ferrero D., Grignani F., Korsmeyer S. J., Dala-Favera R. Growth- and tumor-promoting effects of deregulated bcl-2 in human b-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 86:1989;4589.
5. Chen M. K., Strande L., Kain M., Whalen T. V., Doolin E. J. Induction of apoptosis in a neuroblastoma and hepatocyte coculture model. J. Surg. Res. 78:1998;123.
6. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science. 274:1996;1363.
7. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by color cancer cells expressing Fas ligand. J. Exp. Med. 184:1996;1075.
8. Rabinovich H., Reichert T. E., Kashii Y., Gastman B. R., Bell M. C., Whiteside T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. J. Clin. Invest. 101:1998;2579.
9. Tanaka M., Suda T., Haze H., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A., Nagata S. Fas ligand in human serum. Nat. Med. 3:1996;317.
10. Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K., Shanahan F. The Fas counter attackin vivo. J. Immunol. 160:1998;5669.
11. Ashkenazi A., Dixit V. M. Death receptors: Signaling and modulation. Science. 281:1998;1305.
12. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233.
13. Suda T., Takahashi T., Goldstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169.
14. Nagata S., Golstein P. The fas death factor. Science. 267:1995;1449.
15. Mariani S., Matiba B., Baumler C., Krammer P. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:1995;2303.
16. Krammer P., Dhein J., Walczak H., Behrman I., Mariani S., Matiba B., Fath M., Daniel P., Knipping E., Westendorp M., Stricker K., Baumler C., Hellbardt S., Germer M., Peter M., Debatin K. The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 142:1994;175.
17. Muller M., Strand S., Hug H., Heinemann H., Walczak H., Hofmann W., Stremmel W., Krammer P., Galle P. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/FAS) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:1997;403.
18. Kayagaki N., Kawasaki A., Abata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1995;1777.
19. Wanatabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314.
20. Hofmann K., Bucher P., Tschopp J. The CARD domain: A new apoptotic signalling motif. Trends Biochem. Sci. 22:1997;155.
21. Muzio M., Stockwell B. R., Stennicke H. R., Salvesen G. S., Dixit V. M. An induced proximity model for caspase-8 activation. J. Biol. Chem. 273:1998;2926.
22. Tartaglia L. A., Goeddel D. V. Two TNF receptors. Immunol. Today. 13:1997;151.
23. Wong G. H. W., Goeddel D. V. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol. 152:1994;1751.
24. Smith C. A., Farrah R., Goodwin G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell. 76:1994;959.
25. Gruss H. J., Dower K. Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood. 85:1995;3378.
26. Wang C. Y., Mayo M. W., Baldwin A. S. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NK-kappaB. Science. 274:1996;784.
27. Van Antwerp D. J., Martin S. J., Kafri T., Green D., Verma I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274:1996;787.
28. Natoli G., Costanzo A., Guido F., Moretti F., Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem. Pharm. 56:1998;915.
29. Roulston A., Reinhard C., Amiri P., Williams L. T. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J. Biol. Chem. 273:1998;10232.
30. Hsu H., Xiong J., Goeddel D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 81:1995;495.
31. Barksdale, E. 1998.
32. Evans A. E., Baum E., Chard R. Do infants with stage IV-S neuroblastoma need treatments. Arch. Dis. Child. 56:1981;271.
33. Carlsen N. L. T. How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br. J. Cancer. 61:1990;441.
34. Ellis R. E., Yuan J., Horvitz H. R. Mechanisms and functions of cell death. Annu. Rev. Cell. Biol. 7:1991;663.
35. Ni, R. Tomita, Y. Matsuda, K. Ichihara, A. Ishimura, K. Ogasawara, J. Nagata, S. Fas-mediated apoptosis in primary cultured mouse hepatocytes.
36. Feldmann G. Liver apoptosis. J. Hepatol. 26:1997;1.
37. Ogasawara J., Wanatabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effects of the anti-Fas antibody in mice. Nature. 364:1993;806.
38. Galle P. R., Krammer P. H. CD95-induced apoptosis in human liver disease. Semin. Liver Dis. 18:1998;141.
39. Fulda S., Sieverts H., Friesen C., Herr I., Debatin K.-M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57:1997;3823.
40. Nichans G. A., Brunner T., Frizelle S. P., Liston J. C., Salerno C. T., Knapp D. J., Green D. R., Kratzke R. A. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007.
41. Liu Q.-Y., Rubin M. A., Omene C., Lederman S., Stein C. A. Fas ligand is constitutively secreted by prostate cancer cellsin vivo. Clin. Cancer Res. 4:1998;1803.
42. Owen-Schaub L. B., van Golen K. L., Hill L. L., Price J. E. Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. 188:1998;1717.
43. Lutz W., Fulda S., Jeremias I., Debatin K.-M., Schwab M. MycN and IFNγ cooperate in apoptosis of human neuroblastoma cells. Oncogene. 17:1998;339.
44. Lacronique V., Mignon A., Fabre M., Viollet B., Rouquet N., Molina T., Porteu A., Henrion A., Bouscary D., Varlet P., Joulin V., Kahn A. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2:1996;80.
45. Iwai K., Miyawaki T., Takizawa T., Konno A., Ohta K., Yachie A., Seki H., Taniguschi N. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 84:1994;1201.
46. Schneider T. J., Grillot D., Foote L. C., Nunez G. E., Rothstein T. L. Bcl-x protects primary B cells against Fas-mediated apoptosis. J. Immunol. 159:1997;4834.